content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">As filed with the Securities and Exchange
  Commission on October 7, 2020</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration No. ______</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TFF Pharmaceuticals, Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
  its charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>82-4344737</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification No.)</P></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2600 Via Fortuna, Suite 360</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Austin, Texas</B></P></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>78746</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2018 Stock Incentive Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">(Full title
  of the plan)<BR>&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Glenn
  Mattes<BR>
  Chief Executive Officer<BR>
  2600 Via Fortuna, Suite 360<BR>
  Austin, Texas 78746<BR>
  </B></FONT>(Name and address of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(737) 802-1973</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Telephone number, including area code,
  of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Copy to:</I></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Daniel K. Donahue</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Greenberg Traurig, LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18565 Jamboree Road, Suite 500</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Irvine, California 92612</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(949) 732-6500</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions
  of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo; and &ldquo;emerging
  growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Large accelerated filer &#9744;</FONT></TD>
      <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Accelerated filer &#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Non-accelerated filer &#9746;</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Smaller reporting company &#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Emerging growth company &#9746;</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
  registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
  provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Title
  of Securities to be Registered</B></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount to be Registered (1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposed Maximum Offering </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Price per Share</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Proposed Maximum Aggregate Offering Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount of Registration Fee</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="width: 46%; text-align: left">Common Stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">3,284,480 shares</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">17.77</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">(2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">58,365,209</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">(2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,367.65</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">In addition, pursuant to Rule 416(c) under the Securities Act of 1933, as amended (the &ldquo;Securities
  Act&rdquo;), this Registration Statement includes an indeterminate number of additional shares which may be offered and sold as
  a result of anti-dilution provisions described in the above-referenced plan.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the amount of the registration fee and calculated pursuant to Rule 457(h)(1)
  and Rule 457(c) under the Securities Act.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="margin-top: 0; margin-bottom: 0"></P>
  
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a)
  PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>Item&nbsp;1.</B></TD><TD><B>Plan Information</B></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 24, 2018,
  TFF Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) adopted its 2018 Stock Incentive Plan (&ldquo;Plan&rdquo;). The maximum number
  of shares of common stock of the Company that are available for issuance under the Plan is 3,284,480 shares. This Registration
  Statement on Form S-8 is filed with the Securities and Exchange Commission (&ldquo;Commission&rdquo;) for the purposes of registering
  the 3,284,480 shares of the Company&rsquo;s common stock issuable under the Plan.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The document(s) containing
  the information specified in Part I of Form S-8 will be sent or given to participants in the Plan as specified by Rule 428(b)(1)
  under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). Such documents are not being filed with the Commission,
  but constitute, along with the documents incorporated by reference into this Registration Statement, a prospectus that meets the
  requirements of Section&nbsp;10(a) of the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><B>Item&nbsp;2.</B></TD><TD STYLE="text-align: justify"><B>Registrant Information and Employee Plan Annual Information</B></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will furnish
  without charge to each person to whom the prospectus is delivered, upon the written or oral request of such person, a copy of any
  and all of the documents incorporated by reference in Item&nbsp;3 of Part II of this Registration Statement and incorporated by
  reference in the Section&nbsp;10(a) prospectus, other than exhibits to such documents (unless such exhibits are specifically incorporated
  by reference to the information that is incorporated). Written requests should be made to Investor Relations of TFF Pharmaceuticals,
  Inc. at 2600&nbsp;Via Fortuna, Suite&nbsp;360, Austin, Texas 78746; telephone number (737) 802-1973 or to the email address at
  investorinfo@tffpharma.com.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>
  
  <!-- Field: Page; Sequence: 3; Options: NewSection -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Part</B></FONT><B>
  II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE
  REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>Item&nbsp;3.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Incorporation of Certain Documents by Reference </B></FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following documents
  filed by the Company with the Commission are incorporated by reference into this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">The Company&rsquo;s Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020007544/f10k2019_tffpharma.htm">Form 10-K</A> for the fiscal year ended December 31, 2019, which
  was filed on March&nbsp;27, 2020;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">The Company&rsquo;s Amendment No. 1 to Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020010404/f10k2019a1_tffpharma.htm">Form 10-K</A> for the fiscal year ended December&nbsp;31,
  2019, which was filed on April 29, 2020;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">The Company&rsquo;s Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020012260/f10q0320_tffpharma.htm">Form 10-Q</A> for the quarter ended March 31, 2020, which was
  filed on May 14, 2020;</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">The Company&rsquo;s Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020021865/f10q0620_tffpharma.htm">Form 10-Q</A> for the quarter ended June 30, 2020, which was
  filed on August 13, 2020</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">The Company&rsquo;s Current Reports on Form 8-K filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020002287/f8k012720_tffpharmaceuticals.htm">January 31, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020021315/ea125332-8k_tffpharma.htm">August 11, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020028933/ea127539-8k_tffpharma.htm">September 30, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020029506/ea127673-8k_tffpharma.htm">October 1, 2020</A> (excluding any information furnished pursuant to Item 2.02 or Item 7.01 of such Current Report on
  Form 8-K, unless otherwise indicated therein);</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">The description of the Company&rsquo;s common stock in its <A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019020831/f8a12b101519_tffpharma.htm">Form 8-A12B</A>, which was filed on October&nbsp;22,
  2019, and any amendments or reports filed for the purpose of updating this description; and</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify">All reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c),
  14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered
  have been sold or which deregisters all securities then remaining unsold.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>Item&nbsp;4.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Description of Securities </B></FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>Item 5.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Interests of Named Experts and Counsel </B></FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The
  validity of the issuance of the shares of the Company&rsquo;s common stock offered by this Registration Statement has been passed
  upon by Greenberg Traurig, LLP, Irvine, California</FONT>.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>Item 6.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Indemnification of Directors and Officers </B></FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary
  is qualified in its entirety by reference to the complete text of any statutes referred to below and the second amended and restated
  certificate of incorporation of TFF Pharmaceuticals, Inc., a Delaware corporation.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 of the
  General Corporation Law of the State of Delaware (the &ldquo;DGCL&rdquo;) permits a Delaware corporation to indemnify any person
  who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether
  civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the
  fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of
  the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
  against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
  by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably
  believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding,
  had no reasonable cause to believe the person&rsquo;s conduct was unlawful.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the case of an action
  by or in the right of the corporation, Section 145 of the DGCL permits a Delaware corporation to indemnify any person who was or
  is a party or is threatened to be made a party to any threatened, pending or completed action or suit by reason of the fact that
  the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
  as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against
  expenses (including attorneys&rsquo; fees) actually and reasonably incurred by the person in connection with such action, suit
  or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best
  interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which
  such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or
  the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability
  but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses
  that the Court of Chancery or such other court shall deem proper.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 145 of the
  DGCL also permits a Delaware corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer,
  employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or
  agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such
  person and incurred by such person in any such capacity, or arising out of such person&rsquo;s status as such, whether or not the
  corporation would have the power to indemnify such person against such liability under Section 145 of the DGCL.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Article Sixth of our
  Second Amended and Restated Certificate of Incorporation states that to the fullest extent permitted by the DGCL our directors
  shall not be personally liable to us or to our stockholders for monetary damages for breach of fiduciary duty as a director. If
  the DGCL is amended after the date hereof to authorize corporate action further eliminating or limiting the personal liability
  of directors, then the liability of our directors shall be eliminated or limited to the fullest extent permitted by the DGCL, as
  so amended.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Article Seventh of
  our Second Amended and Restated Certificate of Incorporation provides that we shall, to the maximum extent and in the manner permitted
  by the DGCL, indemnify each of our directors, officers and all other persons we have the power to indemnify under Section 145 of
  the DGCL against expenses (including attorneys&rsquo; fees), judgments, fines, settlements and other amounts actually and reasonably
  incurred in connection with any proceeding, arising by reason of the fact that such person is or was a director, officer, employee
  or agent of the Company.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 5 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As permitted by the
  DGCL, we have entered into indemnification agreements with each of our directors and executive officers that require us to indemnify
  such persons against various actions including, but not limited to, third-party actions where such director or executive officer,
  by reason of his or her corporate status, is a party or is threatened to be made a party to an action, or by reason of anything
  done or not done by such director in any such capacity. We intend to indemnify directors and executive officers against all costs,
  judgments, penalties, fines, liabilities, amounts paid in settlement by or on behalf such directors or executive officers and for
  any expenses actually and reasonably incurred by such directors or executive officers in connection with such action, if such directors
  or executive officers acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests
  of the Company, and with respect to any criminal proceeding, had no reasonable cause to believe their conduct was unlawful. We
  also intend to advance to our directors and executive officers expenses (including attorney&rsquo;s fees) incurred by such directors
  and executive officers in advance of the final disposition of any action after the receipt by us of a statement or statements from
  directors or executive officers requesting such payment or payments from time to time, provided that such statement or statements
  are accompanied by an undertaking, by or on behalf of such directors or executive officers, to repay such amount if it shall ultimately
  be determined that they are not entitled to be indemnified against such expenses by us.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indemnification
  agreements also set forth certain procedures that will apply in the event of a claim for indemnification or advancement of expenses,
  including, among others, provisions about providing notice to us of any action in connection with which a director or executive
  officer seeks indemnification or advancement of expenses from us and provisions concerning the determination of entitlement to
  indemnification or advancement of expenses.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
  for liabilities arising under the Securities Act, may be permitted to our directors, officers or persons controlling us pursuant
  to the provisions contained in our Amended and Restated Certificate of Incorporation, Bylaws, the DGCL or otherwise, we have been
  informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and
  is therefore unenforceable. If a claim for indemnification against such liabilities, other than the payment by us of expenses incurred
  or paid by one of our directors, officers or controlling persons in the successful defense of any action, suit, or proceeding,
  is asserted by such director, officer or controlling person, we will, unless in the opinion of our counsel the matter has been
  settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us
  is against public policy as expressed in the Securities Act and will be governed by the final adjudication of this issue.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt"><B>Item 7.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Exemption from Registration Claimed </B></FONT></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 6 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><B>Item 8.</B></TD><TD><B>Exhibits.</B></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 10%; text-align: center"><B><U>Exhibit No.</U></B></TD>
      <TD STYLE="width: 2%">&nbsp;</TD><TD STYLE="text-align: center; width: 56%"><B><U>Description of Exhibits</U></B></TD>
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="width: 30%">&nbsp;</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 8%">
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit </B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>No.</B></P></TD>
      <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 47%; layout-grid-mode: line; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; width: 2%">&nbsp;</TD>
      <TD STYLE="text-align: justify; border-bottom: Black 1.5pt solid; vertical-align: top; width: 41%">
          <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
          <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Method of Filing</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex3-1_tffpharm.htm"><FONT STYLE="font-size: 10pt">Second Amended and Restated Certificate of Incorporation of the Registrant</FONT></A></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August&nbsp;20, 2019.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex3-2_tffpharm.htm"><FONT STYLE="font-size: 10pt">Amended and Restated Bylaws of the Registrant</FONT></A></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August&nbsp;20, 2019.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019019208/fs12019a1ex4-1_tffpharm.htm"><FONT STYLE="font-size: 10pt">Specimen Certificate representing shares of common stock of Registrant</FONT></A></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on September&nbsp;27, 2019.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea127850ex5-1_tffpharma.htm"><FONT STYLE="font-size: 10pt">Opinion and Consent of Greenberg Traurig, LLP</FONT></A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex10-6_tffpharm.htm">TFF Pharmaceuticals, Inc. 2018 Stock Incentive Plan</A></FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Annual Report on Form 10-K filed on March&nbsp;27, 2020</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea127850ex23-1_tffpharma.htm"><FONT STYLE="font-size: 10pt">Consent of Marcum LLP</FONT></A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23.4</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="ea127850ex5-1_tffpharma.htm"><FONT STYLE="font-size: 10pt">Consent of Greenberg Traurig, LLP</FONT></A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Included in Exhibit 5.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: center">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">24.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD><A HREF="#poa"><FONT STYLE="font-size: 10pt">Power of Attorney</FONT></A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify; layout-grid-mode: line"><FONT STYLE="font-size: 10pt">Included on the signature page to this registration statement</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><B>Item 9.</B></TD><TD STYLE="text-align: justify"><B>Undertakings.</B></TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in; text-align: left">(a)</TD><TD STYLE="text-align: justify">The undersigned registrant hereby undertakes:</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: justify">To file, during any period in which offers or sales are being made, a post-effective amendment
  to this registration statement:</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended
  (the &ldquo;Securities Act&rdquo;).</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">To reflect in the prospectus any facts or events arising after the effective date of the registration
  statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental
  change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume
  of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation
  from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission
  pursuant to Rule 424(b) under the Securities Act if, in the aggregate, the changes in volume and price represent no more than a
  20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the
  effective registration statement.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 7 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">To include any material information with respect to the plan of distribution not previously disclosed
  in the registration statement or any material change to such information in the registration statement.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Provided, however, that paragraphs
  (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs
  is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or section
  15(d) of the Exchange Act that are incorporated by reference in the registration statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">That, for the purpose of determining any liability under the Securities Act, each such post-effective
  amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
  securities at that time shall be deemed to be the initial bona fide offering thereof.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify">To remove from registration by means of a post-effective amendment any of the securities being
  registered which remain unsold at the termination of the offering.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The undersigned registrant hereby undertakes that, for purposes of determining any liability under
  the Securities Act, each filing of the registrant&rsquo;s annual report pursuant to Section 13(a) or Section 15(d) of the Securities
  Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) (and where applicable, each filing of an employee benefit plan&rsquo;s
  annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall
  be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
  that time shall be deemed to be the initial bona fide offering thereof.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
  directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant
  has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities
  Act, and is therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
  by the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
  person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter
  has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
  by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 8 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  of filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
  duly authorized, in the city of Austin, Texas on October 7, 2020.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; text-transform: uppercase">TFF PHARMACEUTICALS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 3%">&nbsp;</TD>
      <TD STYLE="width: 37%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><I>/s/ Glenn Mattes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Glenn Mattes</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="poa"></A>POWER OF ATTORNEY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each person whose
  signature appears below hereby constitutes and appoints Glenn Mattes and Kirk Coleman, and each of them, as such person&rsquo;s
  true and lawful attorney-in-fact and agent, each with full powers of substitution and re-substitution, for such person and in such
  person&rsquo;s name, place and stead, in any and all capacities, to sign any or all amendments (including post effective amendments)
  to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with
  the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform
  each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes
  as such person might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his or
  her substitute or substitutes, may lawfully do or cause to be done by virtue thereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
  of the Securities Act of 1933, this Registration Statement has been signed on October 7, 2020 by the following persons in the capacities
  indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 38%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 2%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 60%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 38%"><FONT STYLE="font-size: 10pt"><I>/s/ Glenn Mattes</I></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; width: 2%; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">President, Chief Executive Officer and Director&nbsp;(Principal Executive Officer) </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Glenn Mattes</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Kirk Coleman</I></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Financial Officer (Principal Financial and Accounting Officer)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Kirk Coleman</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Aaron Fletcher, Ph.D.</I></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chairman of the Board</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Aaron Fletcher, Ph.D.</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Brian Windsor, Ph.D</I></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Brian Windsor, Ph.D.</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Robert S. Mills, Jr.</I></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Robert S. Mills, Jr.</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Stephen C. Rocamboli</I></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Stephen C. Rocamboli</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Harlan Weisman, M.D.</I></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Harlan Weisman, M.D.</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Randy Thurman</I></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Randy Thurman</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Malcolm Fairbairn</I></FONT></TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Malcolm Fairbairn</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>
  
  <!-- Field: Page; Sequence: 9 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 8%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>No.</B></FONT></TD>
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 47%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Item</B></FONT></TD>
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; width: 41%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Method of Filing</B></FONT></TD></TR>
  
  <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex3-1_tffpharm.htm"><FONT STYLE="font-size: 10pt">Second Amended and Restated Certificate of Incorporation of the Registrant</FONT></A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August 20, 2019.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex3-2_tffpharm.htm"><FONT STYLE="font-size: 10pt">Amended and Restated Bylaws of the Registrant</FONT></A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August 20, 2019.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019019208/fs12019a1ex4-1_tffpharm.htm"><FONT STYLE="font-size: 10pt">Specimen Certificate representing shares of common stock of Registrant</FONT></A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on September 27, 2019.</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea127850ex5-1_tffpharma.htm"><FONT STYLE="font-size: 10pt">Opinion and Consent of Greenberg Traurig, LLP</FONT></A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex10-6_tffpharm.htm">TFF Pharmaceuticals, Inc. 2018 Stock Incentive Plan</A></FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Annual Report on Form&nbsp;10-K filed on March 27, 2020</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea127850ex23-1_tffpharma.htm"><FONT STYLE="font-size: 10pt">Consent of Marcum LLP</FONT></A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">23.4</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea127850ex5-1_tffpharma.htm"><FONT STYLE="font-size: 10pt">Consent of Greenberg Traurig, LLP</FONT></A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Included in Exhibit 5.1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">24.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="#poa"><FONT STYLE="font-size: 10pt">Power of Attorney</FONT></A></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Included on the signature page to this registration statement</FONT></TD></TR>
  </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">8</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea127850-s8_tffpharma.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 78268}]
metadata_filer: {"company-data": {"conformed-name": "TFF Pharmaceuticals, Inc.", "cik": "0001733413", "assigned-sic": "2834", "irs-number": "824344737", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-249364", "film-number": "201229191"}, "business-address": {"street1": "2600 VIA FORTUNA, SUITE 360", "city": "AUSTIN", "state": "TX", "zip": "78746", "phone": "737-802-1973"}, "mail-address": {"street1": "2600 VIA FORTUNA, SUITE 360", "city": "AUSTIN", "state": "TX", "zip": "78746"}}
text: As filed with the Securities and Exchange
  Commission on October 7, 2020
  Registration No. ______
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  WASHINGTON, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER THE SECURITIES ACT OF 1933
  TFF Pharmaceuticals, Inc.
  (Exact name of registrant as specified in
  its charter)
  Delaware
  82-4344737
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer
  Identification No.)
  2600 Via Fortuna, Suite 360
  Austin, Texas
  78746
  (Address of Principal Executive Offices)
  (Zip Code)
  2018 Stock Incentive Plan
  (Full title
  of the plan)
  Glenn
  Mattes
  Chief Executive Officer
  2600 Via Fortuna, Suite 360
  Austin, Texas 78746
  (Name and address of agent for service)
  (737) 802-1973
  (Telephone number, including area code,
  of agent for service)
  Copy to:
  Daniel K. Donahue
  Greenberg Traurig, LLP
  18565 Jamboree Road, Suite 500
  Irvine, California 92612
  (949) 732-6500
  Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions
  of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging
  growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer ☐
  Accelerated filer ☐
  Non-accelerated filer ☒
  Smaller reporting company ☒
  Emerging growth company ☒
  If an emerging growth company, indicate by check mark if the
  registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
  provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
  CALCULATION OF REGISTRATION FEE
  Title
  of Securities to be Registered
  Amount to be Registered (1)
  Proposed Maximum Offering
  Price per Share
  Proposed Maximum Aggregate Offering Price
  Amount of Registration Fee
  Common Stock
  3,284,480 shares
  $
  17.77
  (2)
  $
  58,365,209
  (2)
  $
  6,367.65
  (1)
  In addition, pursuant to Rule 416(c) under the Securities Act of 1933, as amended (the "Securities
  Act"), this Registration Statement includes an indeterminate number of additional shares which may be offered and sold as
  a result of anti-dilution provisions described in the above-referenced plan.
  (2)
  Estimated solely for the purpose of calculating the amount of the registration fee and calculated pursuant to Rule 457(h)(1)
  and Rule 457(c) under the Securities Act.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a)
  PROSPECTUS
  Item 1.
  Plan Information
  On January 24, 2018,
  TFF Pharmaceuticals, Inc. (the "Company") adopted its 2018 Stock Incentive Plan ("Plan"). The maximum number
  of shares of common stock of the Company that are available for issuance under the Plan is 3,284,480 shares. This Registration
  Statement on Form S-8 is filed with the Securities and Exchange Commission ("Commission") for the purposes of registering
  the 3,284,480 shares of the Company's common stock issuable under the Plan.
  The document(s) containing
  the information specified in Part I of Form S-8 will be sent or given to participants in the Plan as specified by Rule 428(b)(1)
  under the Securities Act of 1933, as amended (the "Securities Act"). Such documents are not being filed with the Commission,
  but constitute, along with the documents incorporated by reference into this Registration Statement, a prospectus that meets the
  requirements of Section 10(a) of the Securities Act.
  Item 2.
  Registrant Information and Employee Plan Annual Information
  The Company will furnish
  without charge to each person to whom the prospectus is delivered, upon the written or oral request of such person, a copy of any
  and all of the documents incorporated by reference in Item 3 of Part II of this Registration Statement and incorporated by
  reference in the Section 10(a) prospectus, other than exhibits to such documents (unless such exhibits are specifically incorporated
  by reference to the information that is incorporated). Written requests should be made to Investor Relations of TFF Pharmaceuticals,
  Inc. at 2600 Via Fortuna, Suite 360, Austin, Texas 78746; telephone number (737) 802-1973 or to the email address at
  investorinfo@tffpharma.com.
  1
  Part
  II
  INFORMATION REQUIRED IN THE
  REGISTRATION STATEMENT
  Item 3.
  Incorporation of Certain Documents by Reference
  The following documents
  filed by the Company with the Commission are incorporated by reference into this Registration Statement:
  (a)
  The Company's Annual Report on
  Form 10-K
  for the fiscal year ended December 31, 2019, which
  was filed on March 27, 2020;
  (b)
  The Company's Amendment No. 1 to Annual Report on
  Form 10-K
  for the fiscal year ended December 31,
  2019, which was filed on April 29, 2020;
  (c)
  The Company's Quarterly Report on
  Form 10-Q
  for the quarter ended March 31, 2020, which was
  filed on May 14, 2020;
  (d)
  The Company's Quarterly Report on
  Form 10-Q
  for the quarter ended June 30, 2020, which was
  filed on August 13, 2020
  (e)
  The Company's Current Reports on Form 8-K filed on
  January 31, 2020
  ,
  August 11, 2020
  ,
  September 30, 2020
  and
  October 1, 2020
  (excluding any information furnished pursuant to Item 2.02 or Item 7.01 of such Current Report on
  Form 8-K, unless otherwise indicated therein);
  (f)
  The description of the Company's common stock in its
  Form 8-A12B
  , which was filed on October 22,
  2019, and any amendments or reports filed for the purpose of updating this description; and
  (g)
  All reports and other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c),
  14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered
  have been sold or which deregisters all securities then remaining unsold.
  2
  Item 4.
  Description of Securities
  Not applicable.
  Item 5.
  Interests of Named Experts and Counsel
  The
  validity of the issuance of the shares of the Company's common stock offered by this Registration Statement has been passed
  upon by Greenberg Traurig, LLP, Irvine, California
  .
  Item 6.
  Indemnification of Directors and Officers
  The following summary
  is qualified in its entirety by reference to the complete text of any statutes referred to below and the second amended and restated
  certificate of incorporation of TFF Pharmaceuticals, Inc., a Delaware corporation.
  Section 145 of the
  General Corporation Law of the State of Delaware (the "DGCL") permits a Delaware corporation to indemnify any person
  who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether
  civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the
  fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of
  the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
  against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
  by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably
  believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding,
  had no reasonable cause to believe the person's conduct was unlawful.
  In the case of an action
  by or in the right of the corporation, Section 145 of the DGCL permits a Delaware corporation to indemnify any person who was or
  is a party or is threatened to be made a party to any threatened, pending or completed action or suit by reason of the fact that
  the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
  as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against
  expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with such action, suit
  or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best
  interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which
  such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or
  the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability
  but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses
  that the Court of Chancery or such other court shall deem proper.
  Section 145 of the
  DGCL also permits a Delaware corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer,
  employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or
  agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such
  person and incurred by such person in any such capacity, or arising out of such person's status as such, whether or not the
  corporation would have the power to indemnify such person against such liability under Section 145 of the DGCL.
  Article Sixth of our
  Second Amended and Restated Certificate of Incorporation states that to the fullest extent permitted by the DGCL our directors
  shall not be personally liable to us or to our stockholders for monetary damages for breach of fiduciary duty as a director. If
  the DGCL is amended after the date hereof to authorize corporate action further eliminating or limiting the personal liability
  of directors, then the liability of our directors shall be eliminated or limited to the fullest extent permitted by the DGCL, as
  so amended.
  Article Seventh of
  our Second Amended and Restated Certificate of Incorporation provides that we shall, to the maximum extent and in the manner permitted
  by the DGCL, indemnify each of our directors, officers and all other persons we have the power to indemnify under Section 145 of
  the DGCL against expenses (including attorneys' fees), judgments, fines, settlements and other amounts actually and reasonably
  incurred in connection with any proceeding, arising by reason of the fact that such person is or was a director, officer, employee
  or agent of the Company.
  3
  As permitted by the
  DGCL, we have entered into indemnification agreements with each of our directors and executive officers that require us to indemnify
  such persons against various actions including, but not limited to, third-party actions where such director or executive officer,
  by reason of his or her corporate status, is a party or is threatened to be made a party to an action, or by reason of anything
  done or not done by such director in any such capacity. We intend to indemnify directors and executive officers against all costs,
  judgments, penalties, fines, liabilities, amounts paid in settlement by or on behalf such directors or executive officers and for
  any expenses actually and reasonably incurred by such directors or executive officers in connection with such action, if such directors
  or executive officers acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests
  of the Company, and with respect to any criminal proceeding, had no reasonable cause to believe their conduct was unlawful. We
  also intend to advance to our directors and executive officers expenses (including attorney's fees) incurred by such directors
  and executive officers in advance of the final disposition of any action after the receipt by us of a statement or statements from
  directors or executive officers requesting such payment or payments from time to time, provided that such statement or statements
  are accompanied by an undertaking, by or on behalf of such directors or executive officers, to repay such amount if it shall ultimately
  be determined that they are not entitled to be indemnified against such expenses by us.
  The indemnification
  agreements also set forth certain procedures that will apply in the event of a claim for indemnification or advancement of expenses,
  including, among others, provisions about providing notice to us of any action in connection with which a director or executive
  officer seeks indemnification or advancement of expenses from us and provisions concerning the determination of entitlement to
  indemnification or advancement of expenses.
  Insofar as indemnification
  for liabilities arising under the Securities Act, may be permitted to our directors, officers or persons controlling us pursuant
  to the provisions contained in our Amended and Restated Certificate of Incorporation, Bylaws, the DGCL or otherwise, we have been
  informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and
  is therefore unenforceable. If a claim for indemnification against such liabilities, other than the payment by us of expenses incurred
  or paid by one of our directors, officers or controlling persons in the successful defense of any action, suit, or proceeding,
  is asserted by such director, officer or controlling person, we will, unless in the opinion of our counsel the matter has been
  settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us
  is against public policy as expressed in the Securities Act and will be governed by the final adjudication of this issue.
  Item 7.
  Exemption from Registration Claimed
  Not applicable.
  4
  Item 8.
  Exhibits.
  Exhibit No.
  Description of Exhibits
  Exhibit
  No.
  Description
  Method of Filing
  3.1
  Second Amended and Restated Certificate of Incorporation of the Registrant
  Incorporated by reference from the Registrant's Registration Statement on Form S-1 filed on August 20, 2019.
  3.2
  Amended and Restated Bylaws of the Registrant
  Incorporated by reference from the Registrant's Registration Statement on Form S-1 filed on August 20, 2019.
  4.1
  Specimen Certificate representing shares of common stock of Registrant
  Incorporated by reference from the Registrant's Registration Statement on Form S-1 filed on September 27, 2019.
  5.1
  Opinion and Consent of Greenberg Traurig, LLP
  Filed electronically herewith
  10.1
  TFF Pharmaceuticals, Inc. 2018 Stock Incentive Plan
  Incorporated by reference from the Registrant's Annual Report on Form 10-K filed on March 27, 2020
  23.1
  Consent of Marcum LLP
  Filed electronically herewith
  23.4
  Consent of Greenberg Traurig, LLP
  Included in Exhibit 5.1
  24.1
  Power of Attorney
  Included on the signature page to this registration statement
  Item 9.
  Undertakings.
  (a)
  The undersigned registrant hereby undertakes:
  (1)
  To file, during any period in which offers or sales are being made, a post-effective amendment
  to this registration statement:
  (i)
  To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended
  (the "Securities Act").
  (ii)
  To reflect in the prospectus any facts or events arising after the effective date of the registration
  statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental
  change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume
  of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation
  from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission
  pursuant to Rule 424(b) under the Securities Act if, in the aggregate, the changes in volume and price represent no more than a
  20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the
  effective registration statement.
  5
  (iii)
  To include any material information with respect to the plan of distribution not previously disclosed
  in the registration statement or any material change to such information in the registration statement.
  Provided, however, that paragraphs
  (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs
  is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or section
  15(d) of the Exchange Act that are incorporated by reference in the registration statement.
  (2)
  That, for the purpose of determining any liability under the Securities Act, each such post-effective
  amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
  securities at that time shall be deemed to be the initial bona fide offering thereof.
  (3)
  To remove from registration by means of a post-effective amendment any of the securities being
  registered which remain unsold at the termination of the offering.
  (b)
  The undersigned registrant hereby undertakes that, for purposes of determining any liability under
  the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Securities
  Exchange Act of 1934, as amended (the "Exchange Act") (and where applicable, each filing of an employee benefit plan's
  annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall
  be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
  that time shall be deemed to be the initial bona fide offering thereof.
  (c)
  Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
  directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant
  has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities
  Act, and is therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment
  by the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling
  person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter
  has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
  by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
  6
  SIGNATURES
  Pursuant to the requirements
  of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
  of filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
  duly authorized, in the city of Austin, Texas on October 7, 2020.
  TFF PHARMACEUTICALS, INC.
  By:
  /s/ Glenn Mattes
  Glenn Mattes
  Chief Executive Officer
  POWER OF ATTORNEY
  Each person whose
  signature appears below hereby constitutes and appoints Glenn Mattes and Kirk Coleman, and each of them, as such person's
  true and lawful attorney-in-fact and agent, each with full powers of substitution and re-substitution, for such person and in such
  person's name, place and stead, in any and all capacities, to sign any or all amendments (including post effective amendments)
  to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with
  the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform
  each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes
  as such person might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his or
  her substitute or substitutes, may lawfully do or cause to be done by virtue thereof.
  Pursuant to the requirements
  of the Securities Act of 1933, this Registration Statement has been signed on October 7, 2020 by the following persons in the capacities
  indicated.
  Signature
  Title
  /s/ Glenn Mattes
  President, Chief Executive Officer and Director (Principal Executive Officer)
  Glenn Mattes
  /s/ Kirk Coleman
  Chief Financial Officer (Principal Financial and Accounting Officer)
  Kirk Coleman
  /s/ Aaron Fletcher, Ph.D.
  Chairman of the Board
  Aaron Fletcher, Ph.D.
  /s/ Brian Windsor, Ph.D
  Director
  Brian Windsor, Ph.D.
  /s/ Robert S. Mills, Jr.
  Director
  Robert S. Mills, Jr.
  /s/ Stephen C. Rocamboli
  Director
  Stephen C. Rocamboli
  /s/ Harlan Weisman, M.D.
  Director
  Harlan Weisman, M.D.
  /s/ Randy Thurman
  Director
  Randy Thurman
  /s/ Malcolm Fairbairn
  Director
  Malcolm Fairbairn
  7
  INDEX TO EXHIBITS
  No.
  Item
  Method of Filing
  3.1
  Second Amended and Restated Certificate of Incorporation of the Registrant
  Incorporated by reference from the Registrant's Registration Statement on Form S-1 filed on August 20, 2019.
  3.2
  Amended and Restated Bylaws of the Registrant
  Incorporated by reference from the Registrant's Registration Statement on Form S-1 filed on August 20, 2019.
  4.1
  Specimen Certificate representing shares of common stock of Registrant
  Incorporated by reference from the Registrant's Registration Statement on Form S-1 filed on September 27, 2019.
  5.1
  Opinion and Consent of Greenberg Traurig, LLP
  Filed electronically herewith
  10.1
  TFF Pharmaceuticals, Inc. 2018 Stock Incentive Plan
  Incorporated by reference from the Registrant's Annual Report on Form 10-K filed on March 27, 2020
  23.1
  Consent of Marcum LLP
  Filed electronically herewith
  23.4
  Consent of Greenberg Traurig, LLP
  Included in Exhibit 5.1
  24.1
  Power of Attorney
  Included on the signature page to this registration statement
  8